Form 4: Viking Global Investors Sells 3.5 Million Shares of BridgeBio Pharma

Viking Global Investors LP, a 10% owner and director of BridgeBio Pharma, Inc., has reported the sale of 3.5 million shares of common stock for $44 per share.

Summary

• Viking Global Investors LP and its affiliated entities, including Viking Global Opportunities Illiquid Investments Sub-Master LP, sold a total of 3,500,000 shares of BridgeBio Pharma, Inc. common stock.
• The transaction occurred on June 27, 2025, with shares sold at a price of $44 per share.
• Following this sale, Viking Global Investors LP and its affiliated entities beneficially own 18,555,375 shares of BridgeBio Pharma, Inc. common stock.
• The sold shares included 155,000 from Viking Global Equities Master Ltd., 61,690 from Viking Long Fund Master Ltd., and 3,283,310 from Viking Global Opportunities Illiquid Investments Sub-Master LP.
• The remaining beneficial ownership includes 332,901 shares held by Viking Global Equities Master Ltd., 132,494 by Viking Long Fund Master Ltd., and 18,089,980 by Viking Global Opportunities Illiquid Investments Sub-Master LP.

Sentiment

Score: 3

Explanation: The sentiment is negative due to a large insider sale by a significant institutional investor and director, which can imply reduced confidence or a strategic divestment.

Negatives

• A significant sale of 3.5 million shares by a 10% owner and director, Viking Global Investors LP, could be perceived negatively by the market, potentially signaling a reduction in confidence or a strategic portfolio rebalancing away from BridgeBio Pharma, Inc.

Future Outlook

No forward-looking statements or guidance are provided in this document.

Management Comments

• The Reporting Persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the 'Exchange Act'), or for any other purpose.

Industry Context

This Form 4 filing details a specific insider transaction by a major institutional investor in a biotechnology company. It does not provide broader industry trends or context beyond the transaction itself.

Related Party Transactions

• Sale of 3,500,000 shares of Common Stock by Viking Global Investors LP and its affiliated entities, which are 10% owners and directors of BridgeBio Pharma, Inc.

Stakeholder Impact

• Shareholders may react negatively to the news of a significant sale by a major institutional investor and director, potentially leading to a decrease in share price due to concerns about the company's outlook or the investor's confidence.

Key Dates

Recommendation

Keywords

BridgeBio Pharma, BBIO, Viking Global Investors, Insider Sale, Form 4, Beneficial Ownership, Stock Transaction, Institutional Investor